12:00 AM
Feb 14, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

StreptAvax: IDBE said that in a dose-escalation 30-patient Phase I study, a 50 mg dose of the vaccine was safe and well tolerated in all 10 patients receiving t

ID Biomedical Corp. (IDBE; TSE:IDB), Vancouver, B.C.
Product: StreptAvax
Business: Infectious diseases
Therapeutic category: Immune stimulation
Target: Immune cells

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >